Delving into the Latest Updates on Hepatitis A inactivated & hepatitis B (recombinant) vaccine(GlaxoSmithKline Plc) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine

Synonyms

Ambirix, Hepatitis A-hepatitis B vaccine, Twinrix Adult

+ [6]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis AHepatitis B

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

GlaxoSmithKline Biologicals SAGlaxoSmithKline LLC

Inactive Organization

GSK Plc

Drug Highest PhaseApproved

First Approval Date

EU (19 Sep 1996),

Hepatitis AHepatitis B

Regulation-

Login to view First Approval Timeline

Gene Sequence

Sequence Code 160473134

Previous studies have shown that 5-10% of Hepatitis B Virus vaccine recipients produce none or to few antibodies after a standard immunization with 3 vaccines. These individuals are defined as non-responders. The investigators wish to investigate if mounting another kind of immune response, called the cellular immune (CMI) response, protects these non-responders.
Aim/Hypothesis
Primary aims:
To estimate the CMI response in serologic non-responders after receiving a standard course of HBV immunization
Secondary aims:
To establish the prevalence of serological non-responders after a standard course of HBV vaccination.
To assess the safety of the vaccine.
Evaluate predictors of serologic non-response in young, healthy individuals receiving a standard course of HBV immunization
To compare the immunological profile before and after a standard HBV vaccination regimen on non-responders and responders
Establish a rapid test for measuring CMI after being HBV vaccinated.
A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months. Blood is drawn at 0 and 8 months from all participants. The blood will be analysed to see if there is antibodies or/and if there is mounted a cellular immune response by measuring on parameters called cytokines.

Start Date01 Oct 2011

Sponsor / Collaborator

University of Aarhus

[+2]

100 Clinical Results associated with Hepatitis A inactivated & hepatitis B (recombinant) vaccine(GlaxoSmithKline Plc)

Login to view more data

100 Translational Medicine associated with Hepatitis A inactivated & hepatitis B (recombinant) vaccine(GlaxoSmithKline Plc)

Login to view more data

100 Patents (Medical) associated with Hepatitis A inactivated & hepatitis B (recombinant) vaccine(GlaxoSmithKline Plc)

Login to view more data

78

Literatures (Medical) associated with Hepatitis A inactivated & hepatitis B (recombinant) vaccine(GlaxoSmithKline Plc)

01 Nov 2023·The Lancet Infectious Diseases

Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial

Article

Author: Muratova, Olga ; Fintzi, Jonathan ; Samake, Yacouba ; Gorres, J Patrick ; Healy, Sara A ; Doumbo, Ogobara K ; Hume, Jen C C ; Imeru, Alemush ; Mohan, Rathy ; Kone, Mamady ; Duffy, Patrick E ; Doucoure, M'Bouye ; Sylla, Daman ; Kwan, Jennifer L ; MacDonald, Nicholas J ; O'Connell, Elise M ; Thera, Ismaila ; Niaré, Karamoko ; Salazar-Miralles, Fernando ; Sagara, Issaka ; Diarra, Balla ; Sissoko, Kourane ; Jones, David S ; Narum, David L ; Rausch, Kelly M ; Zaidi, Irfan ; Duan, Junhui ; Swihart, Bruce J ; Zhu, Daming ; Assadou, Mahamadoun H ; Morrison, Robert D ; Traore, Sekou F ; Coulibaly, Mamadou B ; Kamate, Bourama ; Neal, Jillian ; Guindo, Merepen A ; Anderson, Charles F ; Wu, Yimin ; Dolo, Amagana

BACKGROUNDMalaria transmission-blocking vaccines target mosquito-stage parasites and will support elimination programmes. Gamete vaccine Pfs230D1-EPA/Alhydrogel induced superior activity to zygote vaccine Pfs25-EPA/Alhydrogel in malaria-naive US adults. Here, we compared these vaccines in malaria-experienced Malians.METHODSWe did a pilot safety study then double-blind, block-randomised, comparator-controlled main-phase trial in malaria-intense Bancoumana, Mali. 18-50-year-old healthy non-pregnant, non-breastfeeding consenting adult residents were randomly assigned (1:1:1:1) to receive four doses at months 0, 1, 4·5, and 16·5 of either 47 μg Pfs25, 40 μg Pfs230D1 or comparator (Twinrix or Menactra)-all co-administered with normal saline for blinding-or 47 μg Pfs25 plus 40 μg Pfs230D1 co-administered. We documented safety and tolerability (primary endpoint in the as-treated populations) and immunogenicity (secondary endpoint in the as-treated populations: ELISA, standard-membrane-feeding assay, and mosquito direct skin feed assay). This trial is registered at ClinicalTrials.gov, NCT02334462.FINDINGSBetween March 19, and June 2, 2015, we screened 471 individuals. Of 225 enrolled for the pilot and main cohorts, we randomly assigned 25 participants to pilot safety cohort groups of five (20%) to receive a two-dose series of Pfs25-EPA/Alhydrogel (16 μg), Pfs230D1-EPA/Alhydrogel (15 μg) or comparator, followed by Pfs25-EPA/Alhydrogel (16 μg) plus Pfs230D1-EPA/Alhydrogel (15 μg) or comparator plus saline. For the main cohort, we enrolled 200 participants between May 11 and June 2, 2015, to receive a four-dose series of 47 μg Pfs25-EPA/Alhydrogel plus saline (n=50 [25%]; Pfs25), 40 μg Pfs230D1-EPA/Alhydrogel plus saline (n=49 [25%]; Pfs230D1), 47 μg Pfs25-EPA/Alhydrogel plus 40 μg Pfs230D1-EPA/Alhydrogel (n=50 [25%]; Pfs25 plus Pfs230D1), or comparator (Twinrix or Menactra) plus saline (n=51 [25%]). Vaccinations were well tolerated in the pilot safety and main phases. Most vaccinees became seropositive after two Pfs230D1 or three Pfs25 doses; peak titres increased with each dose thereafter (Pfs230D1 geometric mean: 77·8 [95% CI 56·9-106·3], 146·4 [108·3-198·0], and 410·2 [301·6-558·0]; Pfs25 geometric mean 177·7 [130·3-242·4] and 315·7 [209·9-474·6]). Functional activity (mean peak transmission-reducing activity) appeared for Pfs230D1 (74·5% [66·6-82·5]) and Pfs25 plus Pfs230D1 (68·6% [57·3-79·8]), after the third dose and after the fourth dose (88·9% [81·7-96·2] for Pfs230D1 and 85·0% [78·4-91·5] Pfs25 plus Pfs230D1) but not for Pfs25 (58·2% [49·1-67·3] after the third dose and 58·2% [48·5-67·9] after the fourth dose). Pfs230D1 transmission-reducing activity (73·7% [64·1-83·3]) persisted 10 weeks after the fourth dose. Transmission-reducing activity of 80% was estimated at 1659 ELISA units for Pfs25, 218 for Pfs230D1, and 223 for Pfs230D1 plus Pfs25. After 3850 direct skin feed assays, 35 participants (12 Pfs25, eight Pfs230D1, five Pfs25 plus Pfs230D1, and ten comparator) had transmitted parasites at least once. The proportion of positive assays in vaccine groups (Pfs25 33 [3%] of 982 [-0·013 to 0·014], Pfs230D1 22 [2%] of 954 [-0·005 to 0·027], and combination 11 [1%] of 940 [-0·024 to 0·002]) did not differ from that of the comparator (22 [2%] of 974), nor did Pfs230D1 and combination groups differ (-0·024 to 0·001).INTERPRETATIONPfs230D1 but not Pfs25 vaccine induces durable serum functional activity in Malian adults. Direct skin feed assays detect parasite transmission to mosquitoes but increased event rates are needed to assess vaccine effectiveness.FUNDINGIntramural Research Program of the National Institute of Allergy and Infectious Diseases and US National Institutes of Health.

30 Nov 2022·Human Vaccines & Immunotherapeutics

Modeling long-term persistence after 8 years of hepatitis B booster vaccination in 5- to 15-year-old children

Article

Author: Qiu, Yan ; Shen, Ling-Zhi ; Sun, Yu-Jing ; Liu, Ying ; Ren, Jing-Jing ; Wu, Jie ; Wu, Zi-Kang ; Ren, Wen ; Yao, Jun

Vaccination remains the most effective and cost-saving measure to protect against hepatitis B, a global health problem. It is crucial to characterize the persistence of the immune response after booster vaccination. This study aimed to quantify the persistence through mathematical modeling. Booster vaccination against hepatitis B was conducted in children 5-15 years in 2009-10 in Zhejiang Province. There were four dosage formulations of hepatitis B vaccines [Shenzhenkangtai Biotechnology Co. Ltd. Dalianhanxin Biotechnology Co. Ltd. NCPC GeneTech Biotechnology Pharmaceutical Co. Ltd. Sinovac Biotech Co. LTD. China]: 5, 10, and 20 μg hepatitis B vaccines or 5 μg hepatitis A and B (HAB) combination vaccine with a 0-1-6-month schedule. These were randomly administered to children negative for all hepatitis B markers, named as the schedule 2 group. Anti-HBs positive subjects were given one dose of booster, named as the schedule 1 group. Anti-HBs antibody was measured 1, 7, 18, 66, and 102 months after the first booster dose. A linear mixed-effects model was proposed to predict long-term persistence. One hundred two months after the booster dose, the mean anti-HBs levels were 33.8 mIU/mL, with 73.7 mIU/mL for the schedule 1 group and 20.2 mIU/mL for the schedule 2 group. The model predicted that 99.5% of subjects would remain seropositive (≥10mIU/mL) at year 20 post booster vaccination, with 100.0% and 98.8% for the schedule 1 group and the schedule 2 group, respectively, whereas at year 30, the seropositivity rates would decrease to 76.8%, with 99.4% for the schedule 1 group and 62.5% for the schedule 2 group. The immunogenicity of the booster vaccination could persist for at least 8 years. Mathematical modeling may predict even longer, up to 30 years of protection.

01 Dec 2020·Infectious Diseases and TherapyQ3 · MEDICINE

Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in Children

Q3 · MEDICINE

ArticleOA

Author: Badur, Selim ; Mitra, Monjori ; Ota, Martin O C ; Kolhapure, Shafi ; Agrawal, Ashish ; Andani, Anar ; Karkada, Naveen

INTRODUCTIONHepatitis A virus infection is more severe in adults than children. Although vaccination can protect adults, current childhood programs cover a large population more successfully. Childhood vaccination is, therefore, a solution to protecting adults if it induces lasting immunity. Fifteen-year protection has been demonstrated in children, but longer-term data are only available for adults. We aimed to predict long term persistence of antibody in children beyond 15 years and assess if immunological mechanisms triggered by vaccination support longer-term protection.METHODSLong-term clinical studies using hepatitis A (HAV) or A/B vaccines (HAB) containing 720 or 1440 Enzyme-linked immunosorbent assay Units (EU) of hepatitis A virus antigen were identified. Duration of persistence of antibodies and possible protection was determined by descriptively comparing antibody geometric mean concentration (GMC) kinetics, as well as GMC (95% confidence interval) at 15 years post-vaccination across studies. Immunological mechanism studies describing hepatitis A vaccination were identified.RESULTSOne study in children 12-15 years (2-dose HAB 720) and four in adults (2-dose HAV 1440 and 3-dose HAB 720) showed comparable GMC kinetics and per year rates of change up to 15 years. At 15 years, the GMC in children [414.7 mEU/ml (336.9; 510.5)] was in the same range as in adults [range 282.6 (217.6; 367.0) to 550.1 (416.0; 727.4)]. Based on these data, mathematical model predictions from adult studies (showing > 85% protected at 50 years) were deemed likely to also apply to children. Studies identified, both humoral and cell-mediated responses are induced following vaccination.CONCLUSIONBased on comparable antibody data in adults and children up to 15 years, similar longer-term antibody persistence is expected in children with 2-dose inactivated hepatitis A 720 containing vaccine at least up to 50 years. Accordingly, improving routine childhood hepatitis A vaccination coverage could protect against more severe disease in adulthood. Fig. 1 Plain language summary TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT00875485, NCT01000324, NCT01037114, NCT00289757, NCT00291876.

1

News (Medical) associated with Hepatitis A inactivated & hepatitis B (recombinant) vaccine(GlaxoSmithKline Plc)

11 Nov 2023

·www.prnewswire.com

Global HBV Vaccine Market Set to Reach $2.47 Billion by 2023, Driven by Rising HBV Cases Among Infants

DUBLIN, Nov. 10, 2023 /PRNewswire/ -- The "Global Hepatitis B Virus (HBV) Vaccine Market (by End User, Composition, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The global hepatitis B virus (HBV) vaccine market is on a growth trajectory, expected to reach a market value of US$2.47 billion by 2023, with a robust Compound Annual Growth Rate (CAGR) of 5.33% during the projected period. Hepatitis B virus (HBV) is a liver-infecting virus transmitted through various means, including contact with infected blood or bodily fluids, sexual contact, sharing needles, or exposure in healthcare settings. Perinatal transmission from infected mothers to newborns is also a significant concern. HBV Vaccine: Key to Eradicating Hepatitis B The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030. Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines. Vaccine recommendations have evolved over time, now advocating for universal HBV immunization for all individuals under the age of 60. Segmentation The global HBV vaccine market is segmented by end-user into Adult and Pediatric categories. The Adult HBV vaccine segment further divides into mono vaccine and combination vaccine subsegments. Combination vaccines are expected to experience the fastest growth during the forecast period, offering protection against multiple causal agents and reducing individual vaccine packaging costs. For instance, the Twinrix combination vaccine provides protection against both hepatitis B and hepatitis A. Geographic Insights Geographically, the global HBV vaccine market is divided into five regions: The US, China, European Union, Japan, and the Rest of the World (ROW). The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats. Factors such as increasing HBV prevalence, government initiatives promoting vaccination, technological advancements in vaccine production, and rising healthcare expenditure are expected to sustain market growth. The European Union and the UK are poised for significant expansion, driven by improved healthcare infrastructure, active government efforts to combat HBV, and established hospital reimbursement systems. Ongoing technological advancements, increased accessibility, and rising disposable income will further boost HBV vaccination in the European region. Drivers: Rising HBV Cases Among Infants The growing incidence of HBV infection among infants is fueling the demand for HBV vaccines. Perinatal transmission of HBV poses a substantial public health challenge, leading to chronic HBV infection in infants. Chronic HBV infection can result in severe health complications, including liver cirrhosis and liver cancer. To prevent perinatal transmission, the WHO recommends testing all pregnant women for HBV infection and vaccinating infants of HBV-positive mothers soon after birth. The increasing prevalence of HBV among infants is driving greater demand for HBV vaccines as parents seek to protect their children from the virus. Challenge: Inequitable Access to Vaccines Inequitable access to vaccines remains a critical issue, particularly in impoverished areas where awareness and initiatives have faced barriers. Limited access to vaccines may be attributed to challenges such as insufficient storage facilities, lack of government support in remote regions, low literacy rates, limited health knowledge, and financial constraints. Furthermore, the unequal development and distribution of HBV vaccines and antibodies in underserved areas hinder market growth. Trend: AI Revolutionizes Vaccine and Drug Design Recent advancements in biochemistry, structural biology, immunology, microbiology, genomics, and data science have opened doors for innovation. Bioinformatics, harnessing computer techniques for biological sciences, has led to immunoinformatics, which leverages artificial intelligence and machine learning to predict complex immune system activities, such as B cell and T cell epitope prediction. The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth. COVID-19 Impact The COVID-19 pandemic significantly impacted the HBV vaccine market by disrupting vaccine production and supply chains. Shortages of raw materials and transportation disruptions led to vaccine shortages in some regions. Additionally, pandemic-related funding shifts affected vaccination programs, including HBV initiatives. However, post-COVID prospects for the HBV vaccine market are promising. The COVAX Facility, led by WHO, has worked to ensure access to essential vaccines, including HBV vaccines. More than 2 billion doses of HBV vaccines have been secured and delivered globally through this initiative, supporting HBV vaccine production in the post-COVID era. Analysis of Key Players The global HBV vaccine market exhibits moderate concentration with growing acquisitions, collaborations, and product launches. Key players in the market include Merck & Co., Inc., GlaxoSmithKline, Sanofi, VBI Vaccines Inc., Shenzhen Kangtai Biological Products Co., Ltd., Dynavax Technologies Corporation, Meiji Group (KM Biologics), LG Chem Ltd., Cyrus Poonawalla Group (Serum Institute of India Pvt.), and Indian Immunologicals Limited. Top Impacting Factors Growth Drivers Increasing Geriatric Population Increasing Healthcare Expenditure Growing Instances of HBV Among Infants Increase in Liver Cancer and Cirrhosis Deaths due to HBV Challenges High Cost of Vaccine Development Inequitable Access to Vaccines Trends Use of AI in Vaccine and Drug Design Technological Advancements in Vaccine Administration Favorable Government Initiatives and Policies For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

VaccineDrug Approval

100 Deals associated with Hepatitis A inactivated & hepatitis B (recombinant) vaccine(GlaxoSmithKline Plc)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BC	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatitis A	NO	GlaxoSmithKline Biologicals SA	19 Sep 1996
Hepatitis A	LI	GlaxoSmithKline Biologicals SA	19 Sep 1996
Hepatitis A	IS	GlaxoSmithKline Biologicals SA	19 Sep 1996
Hepatitis A	EU	GlaxoSmithKline Biologicals SA	19 Sep 1996
Hepatitis B	NO	GlaxoSmithKline Biologicals SA	19 Sep 1996
Hepatitis B	EU	GlaxoSmithKline Biologicals SA	19 Sep 1996
Hepatitis B	IS	GlaxoSmithKline Biologicals SA	19 Sep 1996
Hepatitis B	LI	GlaxoSmithKline Biologicals SA	19 Sep 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis A	Phase 3	AU	GSK Plc	01 Sep 2003
Hepatitis B	Phase 3	AU	GSK Plc	01 Sep 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00289731 (CTgov)	Phase 4	Hepatitis A \| Hepatitis B	596	TWINRIX™ (Twinrix Group)	aswzpwrrlm(hucjwqunch) = iqsebiqfls qeczodjauw (muusjtbsgb, snbpmcdsnk - cicaxbvrog) View more	-	03 Oct 2018
				Engerix™-B+HAVRIX™ (Engerix-B+Havrix Group)	haspsobtbm(qtzkvkyeuh) = ipijiladtj cnbxhptfvl (xcudxfgevx, ffwlfstwgu - ylzpzbdjku) View more
NCT01453348 (CTgov)	Phase 3	Hepatitis A \| Hepatitis B \| Meningitis, Meningococcal	252	HepA/B+MenACWY-CRM (HepA/B+MenACWY-CRM)	reqmjjlhrg(wjfxvunfoa) = uzcmiwowdr urmbhxjcrs (cjqdyhxpgm, vvmbwgiqtq - oimijaryop) View more	-	10 Mar 2014
				monovalent hepatitis A vaccine+hepatitis B vaccine+hepatitis A/B vaccine (HepA/B)	reqmjjlhrg(wjfxvunfoa) = qnbrrqybwk urmbhxjcrs (cjqdyhxpgm, wubspirkvf - huuhjeruge) View more
NCT00106964 (CTgov)	Phase 4	Hepatitis B \| HIV Infections	371	Hepatitis B vaccine (1: Engerix 20 mcg)	ouufofmyht(gfvhnyzmni) = lffkauahbv jazxhxjmnv (vxfxutlwlt, efilxxwdch - ykyqdneuop) View more	-	28 Jun 2013
				Hepatitis B vaccine (2: Engerix 40 mcg)	ouufofmyht(gfvhnyzmni) = lbfwvpjwmj jazxhxjmnv (vxfxutlwlt, suobbeyytt - tewivldvmg) View more
NCT00465816 (CTgov)	Phase 3	Meningococcal Infections	611	Nimenrix (Meningococcal vaccine 134612)+Twinrix (Nimenrix + Twinrix Group)	kkiygelcnb(xtqgyyemno) = rcnfgjwcvu xrpscmtgue (pzgyyirhhp, dexnuuurxl - gyxbfgdnuh) View more	-	22 May 2012
				Nimenrix (Meningococcal vaccine 134612) (Nimenrix Group)	kkiygelcnb(xtqgyyemno) = muydpzucug xrpscmtgue (pzgyyirhhp, cgwajvyziv - uiyqklskgu) View more
NCT00289770 (CTgov)	Phase 3	Hepatitis A \| Hepatitis B	50	Twinrix	auurkkgard(erzvdcvzsv) = iuomojzieo xaqmmlagup (xfomtxlykd, gjfxpdfzjl - zlowdvktug) View more	-	23 Feb 2011
NCT00289744 (CTgov)	Phase 3	Hepatitis A \| Hepatitis B	178	TWINRIX™ ADULT (Twinrix Group)	bdjxnwscyr(zgaklgqstn) = cwmrxmtcwo bibufeabir (ldybxigvdm, vyfnqkliis - aqvrscbbqe) View more	-	26 Aug 2010
				Engerix TM (Engerix-B Additional Dose (Adult))	vwrilrrvoc(wirrpfjwmk) = xjlpmfuppc rgcjmizolp (jjxmdrgzet, kemjrxdntt - nflsbyrkdr) View more
NCT00289718 (CTgov)	Phase 3	Hepatitis A \| Hepatitis B	51	Twinrix™ adult (Twinrix Group)	rucmjhipek(oltzewvokr) = dzowgygfms jiqsthbusq (uokeuilhhy, ktbagjmyxs - tecrqulhqv) View more	-	26 Aug 2010
				Twinrix™ adult (TWINRIX GROUP)	ahfcflyogb(sxtjlbdihu) = hhqxggjbgd dovdxtrfgi (lsaigajftn, aqgmhumhng - hvndimxuyu) View more
NCT00578227 (CTgov)	Phase 3	Human Papillomavirus Infection	814	Cervarix™+Twinrix ™ Paediatric (Cervarix™ & Twinrix™ Group)	bnzgwddxku(jknuvrvwrp) = solmkcccez ijcmigilmm (vpgphcsexn, jpinrtrgxx - cmltmjbflt) View more	-	06 Jan 2010
				Cervarix™ (Cervarix™ Group)	qtqvdlunph(ipybusgmqv) = dshbfmqxsy mmsqrfkqfi (nshrlgigee, dlybobnqvf - goztxyjmwh) View more
NCT00684671 (CTgov)	Phase 4	Hepatitis A \| Hepatitis B	506	Twinrix (Twinrix Group)	oeberqkedb(dxcgjfjjoj) = terljslgnq xmpouoahmf (kxxtxlmrqh, ejmtsvcykx - tdkmyhkvlv) View more	-	03 Dec 2009
				Engerix-B+Havrix (Engerix + Havrix Group)	oeberqkedb(dxcgjfjjoj) = uilfxwromd xmpouoahmf (kxxtxlmrqh, fwvaeidpkb - sfqpmpxozz) View more
NCT00197119 (CTgov)	Phase 3	Hepatitis A \| Hepatitis B	244	Twinrix™ Junior (Group Twinrix Junior)	tryzyqfqgu(ruurwndxsr) = hknwsbjltr bsjsphzcio (byzjqzvgad, nhjnznijrb - dnsktwajnb) View more	-	14 Aug 2009
				Twinrix™ Adult (Group Twinrix Adult)	tryzyqfqgu(ruurwndxsr) = udeavwkoyg bsjsphzcio (byzjqzvgad, tdfnyxzxbb - gxhtzrrbfp) View more